Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.

By V. Diehl, J. Franklin, M. Pfreundschuh, B. Lathan, U. Paulus, D. Hasenclever, H. Tesch, R. Herrmann, B. Dörken, H. Müller-hermelink and 2 more. New England Journal of Medicine, 2003

790 citations recorded by the source corpus.

Subfields: Otorhinolaryngology, Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/b7d7c9180fd5dbd3cb8bb0a7448d2c21de579385

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Younes
2. E. Sievers
3. N. Bartlett
4. A. Gopal
5. Robert Chen
6. J. Rosenblatt
7. J. Connors
8. C. Moskowitz

Citations in the corpus

• Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. (2012, background): “Improvements in the use of combined chemotherapy and radiotherapy in advanced-stage, newly diagnosed Hodgkin’s lymphoma (HL) have resulted in durable remission rates of approximately 60% to 80%.(1,2) However, a large fraction of patients with HL are not cured.”
• FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. (2006, neutral): “Yes 31 ( 31 ) 26 (34) 5 (23) No 68 (69) 51 (66) 17 (77)”